SCHEMBL17539151

SCHEMBL17539151

CN(Cc1ccc2c(c1)[C@@H](O)[C@@H](CO)C2)C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.35
SLC6A4 P31645 5/20 0.35
GLS O94925 2/20 0.35
MCHR1 Q99705 1/20 0.33
PDK2 Q15119 2/20 0.33
HTR2A P28223 1/20 0.33
CACNA1G O43497 1/20 0.32
CACNA1B Q00975 1/20 0.32
CACNA1C Q13936 1/20 0.32
CTSL P07711 1/20 0.32
CTSB P07858 1/20 0.32
CTSS P25774 1/20 0.32
CHRM2 P08172 2/20 0.32
CHRM4 P08173 2/20 0.32
CHRM1 P11229 2/20 0.32
GRM2 Q14416 1/20 0.32
ACHE P22303 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17539114 0.91 GLS (0.37) HTR2CSLC6A4GLSMCHR1HTR2A
SCHEMBL19229518 0.87 HTR2C (0.33) HTR2CSLC6A4GLSMCHR1PDK2
SCHEMBL17539139 0.84 GLS (0.37) HTR2CSLC6A4GLSMCHR1HTR2A
SCHEMBL17509620 0.84 GLS (0.39) HTR2CSLC6A4GLSMCHR1PDK2
SCHEMBL17539152 0.81 NFKB1 (0.37) HTR2CSLC6A4GLSMCHR1PDK2
SCHEMBL19236010 0.79 MCHR1 (0.39) HTR2CSLC6A4GLSMCHR1PDK2
SCHEMBL17539112 0.76 GLS (0.39) HTR2CSLC6A4GLSMCHR1HTR2A
SCHEMBL17539107 0.75 GLS (0.37) HTR2CSLC6A4GLSMCHR1HTR2A
SCHEMBL17509608 0.75 GLS (0.41) HTR2CSLC6A4GLSMCHR1HTR2A
SCHEMBL17509617 0.75 MEN1 (0.37) CHRM2CHRM4CHRM1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975848-B2 Inhibitors of HIV-1 entry and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-05-22 US disclosed
US-9975848-B2 Inhibitors of HIV-1 entry and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-05-22 US disclosed
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF BRYN MAWR COLLEGE 2017-08-17 US disclosed
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF BRYN MAWR COLLEGE 2017-08-17 US disclosed
WO-2016025681-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233335-A1 INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF CD4, CD81, ICAM1 HTR2C 3239/4885SLC6A4 3208/4885GLS 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.